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ABSTRACT
Objective: Evaluate evidence of the efficacy, safety,
acceptability and cost-effectiveness of outpatient
parenteral antimicrobial therapy (OPAT) models.
Design: A systematic review.
Data sources: MEDLINE, EMBASE, CINAHL,
Cochrane Library, National Health Service (NHS)
Economic Evaluation Database (EED), Research Papers
in Economics (RePEc), Tufts Cost-Effectiveness
Analysis (CEA) Registry, Health Business Elite, Health
Information Management Consortium (HMIC), Web of
Science Proceedings, International Pharmaceutical
Abstracts, British Society for Antimicrobial
Chemotherapy website. Searches were undertaken from
1993 to 2015.
Study selection: All studies, except case reports,
considering adult patients or practitioners involved in
the delivery of OPAT were included. Studies combining
outcomes for adults and children or non-intravenous
(IV) and IV antibiotic groups were excluded, as were
those focused on process of delivery or clinical
effectiveness of 1 antibiotic over another. Titles/
abstracts were screened by 1 reviewer (20% verified). 2
authors independently screened studies for inclusion.
Results: 128 studies involving >60 000 OPAT
episodes were included. 22 studies (17%) did not
indicate the OPAT model used; only 29 involved a
comparator (23%). There was little difference in
duration of OPAT treatment compared with inpatient
therapy, and overall OPAT appeared to produce
superior cure/improvement rates. However, when
models were considered individually, outpatient
delivery appeared to be less effective, and self-
administration and specialist nurse delivery more
effective. Drug side effects, deaths and hospital
readmissions were similar to those for inpatient
treatment, but there were more line-related
complications. Patient satisfaction was high, with
advantages seen in being able to resume daily activities
and having greater freedom and control. However,
most professionals perceived challenges in providing
OPAT.
Conclusions: There were no systematic differences
related to the impact of OPAT on treatment duration or
adverse events. However, evidence of its clinical benefit
compared with traditional inpatient treatment is lacking,
primarily due to the dearth of good quality comparative
studies. There was high patient satisfaction with OPAT
use but the few studies considering practitioner
acceptability highlighted organisational and logistic
barriers to its delivery.
INTRODUCTION
Delivery of intravenous (IV) antibiotics outside
of the hospital setting (often termed outpatient
parenteral antimicrobial therapy (OPAT)) is
widely accepted as standard practice in many
countries, including the USA and Australia.1 In
the USA alone, an estimated quarter of a
million patients receive IV antibiotics on an
outpatient basis each year,2 and this method of
delivery has been used to treat a wide variety of
infections, among them skin and soft tissue
infections, bone and joint infections, pneumo-
nia, and endocarditis.
Strengths and limitations of this study
▪ This review provides the most comprehensive
picture of outpatient parenteral antimicrobial
therapy (OPAT)-related research in recent years,
bringing together available evidence on the clin-
ical and cost-effectiveness, safety and acceptabil-
ity of community-based antibiotic delivery.
▪ Much of the work in this area is based around
service evaluation and many studies provided
only basic descriptive findings, making it difficult
to grade the quality and robustness of the
evidence.
▪ Although many studies were identified and
included in the review, the definitiveness of its
conclusions related to the clinical benefit of
OPAT over traditional inpatient treatment is
limited by the lack of good quality comparative
studies.
▪ Nonetheless, the synthesis provided by this
review provides much needed evidence to inform
the design and commissioning of OPAT services.
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In recent years, OPAT services have also been devel-
oped in the UK, both in the National Health Service
(NHS) and private sectors.3 It has the potential to
deliver cost efﬁciency savings and improved patient
experience4 through fewer inpatient bed days, anti-
microbial agents that need less frequent administration
and choice of treatment setting. Despite this, implemen-
tation of OPAT is patchy and there is signiﬁcant geo-
graphical variation both in the setting and the
healthcare professions involved. Four primary models of
OPAT delivery are in use: outpatient attendance at a
healthcare facility, patient (or carer) self-administration,
administration by a visiting general nurse and adminis-
tration by a visiting specialist nurse.
The failure to realise the full potential of OPAT in the
UK is due in no small part to the paucity of information
related to optimal delivery, most notably evidence of
effectiveness, associated risks and patient preferences for
this form of treatment. The purpose of this review was to
evaluate existing evidence in relation to the efﬁcacy,
safety, acceptability and cost-effectiveness of different
models of OPAT delivery.
METHODS
Identification of studies
A comprehensive search strategy was developed by an
experienced information specialist ( JW) and a range of
bibliographic sources were searched for the period 1993 to
March 2015: MEDLINE, MEDLINE in process, EMBASE,
CINAHL, International Pharmaceutical Abstracts, the
Cochrane Library, the NHS Economic Evaluation Database
(EED), Research Papers in Economics (RePEc), Tufts
Cost-Effectiveness Analysis (CEA) Registry and Health
Business Elite (HBE). This time frame was selected to take
account of the substantial changes in the organisation of
the NHS and the shift towards more community involve-
ment that have taken place following publication of the
NHS and Community Care Act 1990.5 Two separate
searches were run. The ﬁrst identiﬁed studies of IV antibio-
tics and known models of delivery, while the second identi-
ﬁed reviews of antibiotic use in cellulitis or cystic ﬁbrosis
(infections where OPAT is frequently used) to allow for the
identiﬁcation of delivery models that were unknown to us
and subsequently not considered when identifying terms
for the ﬁrst search.
Supplementary searches of Web of Science Proceedings,
the Health Information Management Consortium
(HMIC) and the website of the British Society for
Antimicrobial Chemotherapy were conducted to identify
relevant unpublished work. In addition, the reference lists
of included studies were reviewed for potentially relevant
papers (see online supplementary appendix 1 for sample
search strategies and list of databases searched).
Criteria for inclusion
Studies evaluating the clinical effectiveness or cost-
effectiveness of an OPAT model, describing or
evaluating patient safety issues associated with OPAT, or
considering the acceptability of OPAT were included.
The population included adult patients treated for any
condition (and/or their carer in the case of acceptability
studies) or practitioners involved in the delivery of
OPAT. Any form of IV antibiotic drug delivery system
(eg, infusion or bolus) was included. Studies of any
research design were considered (with the exception of
single case reports), and no language restrictions were
applied.
Studies were excluded if they considered the costs
related to a model of delivery but did not consider
patient beneﬁt alongside these, or if they made refer-
ence to costs and beneﬁts but did not report speciﬁc
cost-effectiveness data (such as cost per quality-adjusted
life year). Similarly, studies that made reference to clin-
ical effectiveness without reporting speciﬁc patient out-
comes were also excluded. Studies that included
children or that involved multiple routes of antibiotic
delivery were reviewed but excluded if they did not dif-
ferentiate between outcomes for adult patients or for
patients receiving IV treatment, and those of other parti-
cipants. Studies that focused only on the method or
process of delivery or on the clinical effectiveness of a
single treatment or of one class of antibiotic over
another were excluded, as were abstract only, descriptive
or commentary pieces and guidance documents.
Selection of studies
Titles and abstracts of all identiﬁed studies were
screened for eligibility by one reviewer (EDM) with a
random selection (20%) independently screened by a
second. Full-text versions of papers not excluded at this
stage were obtained for detailed review and independ-
ently assessed by two reviewers (EDM with CCM, DM or
MT) to determine whether they met the inclusion cri-
teria. Differences of opinion were discussed until a con-
sensus was reached, with validation sought from a third
reviewer where necessary.
Data extraction
Data extraction was carried out by one experienced
reviewer (EDM) using a standardised pro forma. Data
for a sample of studies were extracted independently by
a second reviewer (CCM) in order to validate the items
being collected. Information was collected on study
purpose and design (including factors related to quality
assessment), setting, duration, population and clinical
characteristics, models of delivery (outpatient, self-
administration, general nurse, specialist nurse), outcome
area (clinical effectiveness, cost-effectiveness, safety,
acceptability), antibiotic parameters (type, delivery
route, treatment dose), outcome measures, follow-up
and key ﬁndings.
Assessment of bias
Studies were assessed for bias by two reviewers (EDM
and CCM), where possible using previously developed
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scoring systems. The Cochrane Risk of Bias assessment
tool was used for experimental studies (randomised con-
trolled trials, clinical trials, controlled before and after
studies), and the Newcastle-Ottawa scales for cohort and
case–control studies.6 7
A method of assessing the strength of evidence of
other observational studies—developed for previous
reviews on early diagnosis of cancer8–10—was modiﬁed
for this topic area and applied to relevant studies. In this
system, papers were evaluated on three key areas: popu-
lation, methodology and analysis (see online
supplementary appendix 2). Population assesses the
method used to ensure that a study is appropriately
powered/produces generalisable results, with use of a
sample size calculation or inclusion of all possible
patients or providers rated more highly than selective
recruitment. Methodology assesses procedures for
obtaining study data, with use of a rigorous approach
designed to reduce systematic differences between
groups (selection, characteristics, treatment, etc) rated
more highly than other methods. Analysis assesses use of
analytic techniques, with reporting of relevant signiﬁcant
comparisons or differences (or use of appropriate ana-
lytic techniques if qualitative) rated more highly than
non-statistical comparisons or descriptive data.
Four categories were then used to weight the evi-
dence: STRONG+ (study graded strong in all three
areas); STRONG− (study graded strong in two areas and
moderate in the third); MODERATE (study graded
strong in one area and moderate in two, or moderate in
all three areas); INSUFFICIENT (study used a selective
study population and/or an inappropriate method to
ascertain data, or did not provide enough information
to be able to determine a grading).
Many of the papers included in this review used meth-
odologies that did not lend themselves to the scoring
systems outlined. Many studies included all patients in
receipt of OPAT since its establishment at a particular
institution or over a speciﬁed time period, and simply
reported conditions treated and therapies used, along
with limited outcomes data. Case-series such as these,
which were to all intents and purposes service evalua-
tions that included little or no analytic content, were not
subject to formal quality assessment.
In keeping with accepted good practice, studies at risk
of bias were not excluded from the review, but an
appraisal of the strength of existing evidence has been
reported, and ﬁndings interpreted in light of this.
Data synthesis
The main characteristics of included studies and ﬁndings
relating to clinical effectiveness, cost-effectiveness, patient
safety, acceptability and study quality have been sum-
marised in narrative and tabular form. Substantial hetero-
geneity in clinical characteristics—condition treated,
treatment duration, deﬁnition of a successful outcome
(cure, improvement, deterioration, etc)—and method-
ology precluded pooling of study data for meta-analysis.
Patient involvement
This review formed one work stream of a larger National
Institute for Health Research (NIHR)-funded study that
included qualitative interviews and economic modelling.
The research team included a lay co-applicant who com-
mented on study design prior to submission of the
funding proposal, including the focus of the systematic
review and the outcomes to be included. In addition, a
Patient Advisory Group (PAG) was established to input
at key phases throughout the project including the
design of patient recruitment materials, interview topic
guides and health economics aspects of the study. An
Expert Panel was convened to discuss emerging ﬁndings
from each work stream, and a representative of the PAG
was a member of the panel. A project dissemination
event was held in April 2016 to which both patients and
professionals were invited.
RESULTS
The search strategy identiﬁed 7214 articles of which 589
met the inclusion criteria for detailed review (ﬁgure 1).
The full text of an additional 17 papers, identiﬁed from
the reference lists of previous reviews and identiﬁed
references, was also obtained giving a total of 606 poten-
tially relevant papers. In a change to the initial protocol,
non-English language papers were identiﬁed but were
not assessed for inclusion (n=69), and we were unable to
obtain one article from the library document supply
service. One hundred and twenty-eight papers involving
more than 60 000 OPAT episodes were included in the
ﬁnal analysis.11–138
Population and setting
Three-quarters of studies were undertaken in Europe
(n=53; 41%) and North America (n=45; 35%). Almost
two-thirds of the European studies were UK based. Two
studies involved centres in more than one country,41 101
and one was a systematic review of world literature.60
Studies were comparatively small in size, involving
between 6 and 11 427 participants or episodes of care
(mean 476; median 100); almost two-thirds (63%) had
fewer than 150 participants. It was not possible to deter-
mine total participant numbers in two studies.32 138 The
period under study ranged from 6 weeks to 15 years. In
general, those studies with the largest numbers of parti-
cipants (>1000) either analysed all cases included in an
OPAT registry and/or reviewed cases over a more sub-
stantial time period.18 32 37 41 45 66 76 84 112 130 133
The most commonly reported reason for treatment
was osteomyelitis (n=68, 53%), followed by endocarditis
(n=53, 41%), skin and soft tissue infection (n=41, 32%),
cellulitis (n=32, 25%), and septic arthritis (n=29, 23%).
Most studies involved multiple conditions (n=72, 56%);
7 did not specify indications for treatment. These
included two qualitative studies and one survey of
patient acceptability,16 26 67 three surveys of practitioner
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acceptability63 68 107 and one secondary analysis of data
from an OPAT database.17
Outcomes and OPAT models studied
Of the ﬁve outcome areas evaluated in the review, the
most commonly considered were patient safety (n=109;
85%) and clinical effectiveness (n=89; 70%). Just over a
quarter of studies involved some aspect of patient
acceptability (n=37; 29%), but few determined cost-
effectiveness (n=5) or practitioner acceptability (n=6).
Most investigated multiple areas (70%).
Twenty-two of the 128 studies (17%) either did not
indicate the type of OPAT delivery model used, or
reported that home treatment was used without provid-
ing any additional detail. In the remainder, the most fre-
quently reported model across studies was self (or carer)
administration (n=66; 52%), followed by visits from a
specialist nurse (n=44; 34%), outpatient treatment
(n=35; 27%) and visits from a general nurse (n=14;
11%). Just over half of these studies evaluated a single
model of delivery (n=59; 55%). Other less common
delivery methods and locations included infusion
centres, home infusion or home care companies, hos-
pital in the home units (HHU), prison and doctor visits
(see online supplementary tables S1–S5).
Quality assessment
Few studies employed an experimental or
quasi-experimental design (see online supplementary
tables S1–S5). Most (67%) were observational, primarily
case-series, and many involved retrospective data collec-
tion (n=57; 45%). Of the 12 included randomised con-
trolled trials, 5 reported on subgroup analyses from the
main study and all failed to provide details of the trial
Figure 1 Flow of studies into the review. IV, intravenous; OPAT, outpatient parenteral antimicrobial therapy.
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methodology.15 77 99 100 102 One of two included clinical
trials did not specify the delivery model under
evaluation.39
Many studies analysed data obtained from medical
records or prospectively held OPAT databases (42%); a
small number of others carried out secondary analysis of
national or international OPAT registries. Satisfaction
surveys, either by questionnaire or telephone comple-
tion, were frequently used, while interviews (face-to-face,
telephone, focus group) and visual analogue scales were
also well represented. Less common methods of data col-
lection included clinic or ward diaries, direct observa-
tion, and data from previous studies or the published
literature. It was often unclear who collected data, and
few studies reported on how this was carried out. A sub-
stantial number provided little or no detail on the
methods used. Twenty-one of the 128 (16%) studies
received full or partial funding by pharmaceutical com-
panies, while 72 others (56%) did not report the
funding source.
Risk of bias within studies
Three of the 14 included trials were assessed as having a
low risk of bias,30 103 131 and 1 a high risk of bias (pilot
study where patients self-selected hospital or home treat-
ment and were recruited consecutively to each arm after
this decision was made).40 In the remaining 10 studies,
the level of potential bias was unclear. In ﬁve cases, it
was uncertain whether randomisation or controlling had
taken place. Four of these studies reported on subgroup
analyses from a single open-label trial, and none pro-
vided details of the original study methodology.15 77 99 100
The ﬁfth reported on two related trials comparing IV
with oral treatment for neutropenia in patients with
cancer, and again reported no methodological details of
the parent studies.39 In the remaining ﬁve trials, details
of randomisation, allocation concealment and blinding
(especially in relation to assessment of outcome mea-
sures) were poorly reported.101 102 111 116 132 In addition,
one of the trials closed early due to poor recruitment,87
while population bias due to age and treatment duration
differences could not be excluded from another.132
All ﬁve included case–control studies (three of them
retrospective) rated low for potential bias (median 8/9;
range 6–9).44 78 98 136 137 Those studies scoring lowest did
not provide details on the methods used to determine
outcomes.44 78 Similarly, four cohort studies (two retro-
spective) all had low potential for bias (median 8/9;
range 7–9);12 20 76 112 lower scores related to possible
failure to control for potential differences.20 76
In the majority of observational studies, the data ana-
lysed were derived from OPAT databases or medical
records review. Many studies also involved questionnaire
surveys. Only ﬁve included a comparator (inpatient
care),23 61 75 81 122 with many simply including all OPAT
patients over a selected time period. Most studies
reported descriptive results only, with no statistical
testing of differences.
Impact on clinical outcomes
Only 21 of the 89 studies evaluating the clinical effective-
ness of OPAT included a comparator which, with few
exceptions, was inpatient treatment (table 1; see online
supplementary table S1). Five of the studies did not
specify the OPAT delivery model used,39 75 122 132 136
while two others reported combined results for multiple
models.102 137
Regardless of the particular OPAT model used,
most studies assessing duration of treatment found
little difference compared with inpatient
therapy30 32 40 44 81 98 101 103 131 (table 1). Two studies
(one using specialist nurses,18 the other self-
administration74) found that the average length of OPAT
treatment was shorter. A third study evaluating a HHU
found a signiﬁcant reduction in treatment duration for
patients with cellulitis (median 6 vs 8.6 days; 95% CI
0.24 to 4.85) but not for patients with pyelonephritis
(4.6 vs 4 days; 95% CI −1.86 to 0.72).81
Evidence of the effect of OPAT on cure rate, however,
was less conclusive. When ﬁndings from all delivery
models were considered, OPAT appeared to produce
superior results to those seen for inpatient treatment.
This may reﬂect heterogeneity in the population groups,
with inpatients being thus because they required more
intensive care. However, it is also undoubtedly inﬂu-
enced by the inclusion of positive studies that reported
on multiple or unspeciﬁed OPAT treatment
models.75 102 137 When these were removed and speciﬁc
models considered individually, outpatient delivery
appeared to have a lower rate of cure or improvement
than inpatient treatment (89% vs 95%)101 and self-
administration20 and OPAT by a specialist nurse a
higher rate.44 81 One study found that duration of
neutropenia-related fever in patients with cancer was
signiﬁcantly reduced with specialist nurse-delivered
OPAT (2 vs 5 days; p<0.001),44 and another that rates of
recovery for pyelonephritis were higher (93% vs 90%),62
although this was not the case for cellulitis (93% vs
100%).81 OPAT delivered by a general nurse, however,
had little or no impact on rates of recovery. One study of
treatment for community-acquired pneumonia103 found
no signiﬁcant difference in time to resolution of fever,
tachycardia and tachypnoea, while another found no sig-
niﬁcant difference in days to no advancement of cellu-
litis30 (mean 1.50 vs 1.49; 95% CI −0.3 to 0.28; p=0.90).
Results from studies assessing the impact of OPAT, specif-
ically on lung function in patients with cystic ﬁbrosis,
were either inconclusive or showed no differential
impact.23 40 98 131
In the remaining studies that considered clinical
effectiveness for OPAT models only, rates of cure or
improvement ranged from 61.1% to 100% (mean
89.6%; median 92.5%). When the various OPAT
models were considered individually, the highest
mean cure/improvement rate was found for self-
administration (91.3%), followed by specialist nurse
(90.6%), general nurse (90.0%) and outpatient
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Table 1 Effect of OPAT on clinical success and safety
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treatment (88.3%). Few studies reported on bacterial
eradication, but those that did saw rates of between
57.1% and 100% (mean 86.2%; median 90.0%; see
online supplementary table S1).
Patient safety and adverse events
Only 24 of the 109 studies evaluating OPAT-related safety
included a comparator, which in the majority of cases was
inpatient treatment (table 1; see online supplementary
table S2). Five studies did not specify the OPAT model
being used39 61 75 132 136 and three others reported com-
bined results for multiple models.76 102 137
There was little evidence of impact on either
drug-related side effects or number of deaths in OPAT
patients compared with patients receiving treatment in
hospital20 32 40 44 76 81 98 101 103 109 131 (table 1). One
study evaluating OPAT via outpatient treatment101
reported a higher death rate (1 vs 0 patients), but this
was a small study and the overall rate of side effects was
lower in the OPAT group (15% vs 18%). There also
appeared to be no conclusive evidence of beneﬁt either
in relation to hospital readmissions overall or in relation
to those who self-administered therapy.20 131 There were
conﬂicting results for OPAT delivered by nurses, with spe-
cialist nurses32 78 81 109 appearing to have superior results
to those of general nurses.30 103 Perhaps unsurprisingly,
overall there appeared to be more line-related complica-
tions in IV therapy administered outside of hospital.
Across all studies, the most commonly reported
adverse events were rash, fever, nausea/vomiting, diar-
rhoea, allergic reaction or anaphylaxis, phlebitis, leuco-
penia and line complications (including line infection,
occlusion, breakage and dislodgement; see online
supplementary table S2).
Cost-effectiveness of OPAT
While many of the identiﬁed studies reported on the
cost of OPAT, only ﬁve considered cost-effectiveness (see
online supplementary table S3). Three studies applied
decision tree models to OPAT provided by specialist
nurses,95 119 138 with one also determining the cost-
effectiveness of self-administration.138 The remaining
studies (one literature review, one retrospective observa-
tional study) did not specify the OPAT model(s)
used.60 122
In two of the three decision tree analyses, IV OPAT
was found to be more cost-effective than IV inpatient
therapy.119 138 In one case, it was also more cost-effective
than early discharge with oral therapy and oral out-
patient therapy.119 In the other, its dominance was only
maintained when the IV success rate was >55%.138
Conversely, in the third study, IV OPAT was found to be
less cost-effective than IV to oral switch therapy and oral
treatment, both during and after hospitalisation (which
was the most cost-effective option).95 However, the prob-
ability estimates used in two of the three scenarios in
this study were derived from different data sources (pub-
lished research and institutional data). In addition,
there were no published data related to the baseline
probability for cure in the third scenario, and so this was
assumed to be at some point between the estimates used
in the other two scenarios.
Studies included in the literature review predomin-
antly concluded that home IV antibacterial therapy
would lead to signiﬁcant cost reductions, both from a
societal and third-party payer perspective.60 In 5 of the
11 studies, inpatient therapy was 2–3 times as expensive
as home care therapy. However, there was considerable
variation in the way in which costs were determined and
calculated across studies (eg, incremental costs, costs for
selected components only, etc), while the review itself
lacked considerable detail on the methodology used and
the criteria for study inclusion and exclusion.
Findings from the observational study (based on 435
courses of IV antibiotic treatment for respiratory exacer-
bations in 116 adult patients with cystic ﬁbrosis) indi-
cated that for both 1 course and 1 year of treatment, IV
antibiotic treatment administered mostly in hospital was
more effective but more costly than treatment adminis-
tered mostly at home.122 This improved clinical effective-
ness could only be achieved with the input of
considerable additional resources (between £46 and
£73k per patient at 2002 prices). However, when the
strictest deﬁnition of effectiveness was applied (≤0%
decline in lung function), hospital treatment was
unlikely to ever be cost-effective.
Acceptability of OPAT
Patient preference
Only 4 of the 36 studies considering patients’ acceptabil-
ity of OPAT involved a comparison of inpatient and out-
patient therapy (see online supplementary table S4), 2
where OPAT delivery was by general nurses30 103 and 2
where delivery was by specialist nurses.32 44 In each case,
satisfaction was high, with home treatment seen as bene-
ﬁcial. One of the two general nurse studies found that
only 5% of home group patients would have preferred
hospital treatment, compared with 35% of hospital
patients who would have preferred treatment at home
(p<0.001).30 The other found that patients in the home
group were signiﬁcantly happier with the location of
their care than those receiving inpatient therapy
(p<0.001).103 Similarly, in one of the studies where
patients received home care by specialist nurses, almost
all (97%) indicated that they would choose to receive
at-home therapy in future and would recommend it to
others.44 The main reasons given for this were quiet and
increased home comfort, familiar environment, and free
choice of activity. However, some patients in this study
did report disadvantages to receiving therapy at home,
primarily related to patient and caregiver anxiety.44
In the remaining studies that considered acceptability in
OPAT patients only, most involved multiple OPAT models
(and did not differentiate between them in their ﬁndings),
or did not specify the model(s) under study. For the
most part, satisfaction with treatment was very
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high,11 26 28 42 45 48 51 52 55–57 59 74 89 90 104
105 108 113 120 123 124 including where patients had to have
frequent attendance at hospital.22 135 Commonly perceived
advantages of OPAT included the ability to resume daily
activities,45 56 59 74 feelings of improved self-esteem or
greater freedom and control,48 56 74 82 93 and not having to
remain in or attend hospital.11 56 59 82 118 The main disad-
vantages were most commonly related to infusion equip-
ment, and included anxiety about the device and its
sterility.16 67 97 Two studies found that younger patients
were better able to use infusion devices, and required less
support to do so than older patients.31 67
Two studies determined patients’ willingness to pay to
have treatment in their preferred location, and although
differences did not reach statistical signiﬁcance, patients
reported that they would pay more for the home-based
than hospital-based treatment, including giving up
slightly more of their remaining life to ensure this.73 120
Provider preference
Only six studies included assessment of practitioner
acceptability: one involving general practitioners (GPs),
one involving nurses and four involving infection specia-
lists (see online supplementary table S5). In most cases,
professionals saw advantages (or a need) for patients
receiving IVantibiotic therapy outside of hospital.68 86 93 107
However, there were also negative perceptions in relation
to practitioner involvement. Most GPs saw no advantage to
themselves in home treatment, and many thought distance
from hospital was an issue for patients.93 Similarly, nurses
perceived that there were challenges in providing this
model of care, mainly around the technical nature of the
devices used, and dealing with patients’ understanding of
the technology and its related risks.68 Finally, many specia-
lists saw organisational barriers to the use of OPAT, in
terms of funding, leadership, and the links between
primary and secondary care.63 86–87 107 In addition, there
was no consensus regarding who should assume the cost
or take clinical responsibility for patients.87 107
DISCUSSION
Principal findings
Rates of cure from the published literature, when aggre-
gated, show that there are no systematic differences in
relation to the impact of OPAT on duration of therapy,
or on adverse events associated with IV antibiotic
treatment. In addition, OPAT is, on the whole, more
cost-effective than inpatient care. However, conclusive
evidence as to the clinical beneﬁt (or otherwise) of this
mode of therapy compared with traditional inpatient IV
treatment is lacking. Acceptability of OPAT appears to be
high among patients, who appreciate the greater
freedom that it provides, particularly in relation to being
able to resume daily activities (such as going to work or
school), having greater control over their illness and not
having to attend hospital but being able to stay at home
with family. Disadvantages identiﬁed most commonly
related to the use of infusion equipment. Few studies
considered practitioner acceptability, but those that did
found some concerns related to the logistics involved in
providing an OPAT service, including cost and who
would assume clinical responsibility for patients.
The results of this review should be used by clinicians
in the context of their patient populations and the types
of infection being treated. Results from ongoing
research studies, such as work being done by
Scarborough et al139 to investigate the possibility of early
switch from inpatient IV to oral antibiotics, are likely to
change the way in which patient care is planned and
implemented. However, the results of this review (within
the constraints of the literature) have demonstrated that
OPAT is safe, effective and cost-effective and, as such,
patients are likely to continue to be treated using OPAT
models. In addition, the evidence shows that patients
prefer OPAT, so it is likely that there will be continued
development of community-based services.
Limitations of the study
Although many studies were identiﬁed and included in
this review, its conclusions are limited by the lack of
studies involving a usual care comparison, or comparison
with other models of OPAT delivery. In addition, few
studies employed a rigorous study design. Much of the
work in this area appears to be based around service
evaluation and, as such, many of the studies provided
only basic descriptive ﬁndings, with no estimates of vari-
ance and limited data related to patient outcomes. As a
result, it is difﬁcult to grade the quality and robustness of
the evidence, even in the few randomised controlled
trials that have been conducted. Similarly, substantial clin-
ical and methodological heterogeneity precluded
pooling of data for meta-analysis. The majority of studies
included a varied case-mix and did not differentiate their
results between conditions treated. In addition, there was
variation across studies in relation to what constituted a
successful outcome (cure, improvement, deterioration,
etc), as well as a lack of consistent treatment duration.
Although this undoubtedly reﬂects real-world practice, it
meant that it was not possible to pool the results of indi-
vidual studies to provide estimates of true effect size when
using OPAT for different patient groups, or even for com-
paring OPAT as a whole with inpatient treatment.
Although identiﬁed as part of the search strategy, time
constraints meant that non-English language papers were
not assessed beyond the abstract screening stage, and it is
possible that this may have resulted in some language
bias (through exclusion of negative ﬁndings that may be
more likely to have been published in non-international
journals). However, given the lack of robust, conclusive
studies that were included, this is unlikely to have signiﬁ-
cantly inﬂuenced the ﬁndings of the review.
Implications for clinicians and policymakers
It is likely that the increased use of OPAT in the UK
in recent years is due, in no small part, to clinicians’
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expectations that it should increase hospital inpatient
capacity while delivering non-inferior patient care and
improved patient experience. However, this review has
demonstrated that the evidence related to care is not
strong. Few studies reported on the different levels of
service required to account for the complexity of patient
cases encountered, including those with comorbidity
and those requiring ‘one off’ or longer term treatment.
In addition, many studies provided aggregated results
and it was not possible to disentangle these either for
individual OPAT models or for the speciﬁc conditions
treated. This, combined with a lack of detail on the
delivery models actually used, makes it difﬁcult for clini-
cians and policymakers to be able to replicate existing
practice (and, consequently, potential outcomes) even
from positive studies. OPAT services have the potential
to deliver signiﬁcant cost savings and increased patient
satisfaction for the NHS, and it is crucial that this infor-
mation is reported in future studies in order to identify
best practice and help support decision-making at a
local level. We would recommend, that as a minimum,
authors fully describe the speciﬁc method of OPAT
delivery studied (including deﬁning who delivers ‘spe-
cialist’ nurse care), include and report on a comparator
when determining the impact of OPAT on clinical out-
comes (only 21/89 studies in this review did so), report
all numerators and denominators, avoid reporting
pooled data (where possible), report on case complexity
and average duration of treatment to achieve cure, and
adhere to CONSORT guidelines when reporting trials.
Future research
Commissioning healthcare services in England is
increasingly complex and has been subject to much
change in recent years.140 The NHS England service spe-
ciﬁcation for infectious diseases services141 includes a
requirement to provide OPAT, but at present there is no
clear commissioning mechanism to achieve this. This
review has established that there is currently a dearth of
information around key aspects of OPAT, and it is there-
fore clear that where Clinical Commissioning Groups
have opted to commission OPAT services, they are
working without the support of a robust evidence base.
It is also clear that there is little evidence on which
recommendations for best practice can be based.
Indeed, the main guidance currently in use is the British
Society for Antimicrobial Chemotherapy OPAT standards
document,142 which is a consensus statement largely
derived from expert opinion.
There is a need for further research to address signiﬁ-
cant gaps in knowledge about the cost-effectiveness of
different IV antibiotic services, and to ascertain which
services patients prefer and which aspects of the services
are most important to them. This would help identify
the most appropriate conﬁguration of services in terms
of value for money and patient preference, as well as
future research priorities. Since OPAT services are now
established in many areas of the UK, conducting a
deﬁnite randomised controlled trial of different models
of care is unlikely to be feasible. Individual centres
would not be able to provide all of the necessary com-
parator services for randomisation, and there would be
difﬁculties related to the heterogeneous nature of the
patient population, and consequent decisions about the
most relevant outcome measure. Other, more pragmatic,
study designs should therefore be considered, including
large-scale, prospective observational studies designed to
collect robust data on outcomes, adverse events and the
costs of OPAT (including mixed models of care). This,
together with high standards of reporting to ensure that
delivery models and their results are fully described and
reported individually, would go some way to bridging
the current information gap.
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